The Science of the New Bioeconomy
Our focus begins with the capacity of scientists to read (sequence), comprehend, and write (synthesize) DNA. Ancillary areas expand into genomics, bioinformatics, proteomics, metabolomics, tissue culturing, synthetic biology, and others.
The ethical implications of this science are staggering, and we work hard to be thought leaders on matters of public policy.
The economic implications of this science are also staggering, and we work hard to translate what's going on in the industry into the language of investors and economists.
Our team is particularly sensitive to regulatory issues. We find that investors share our regulatory concerns. We therefore are primarily involved in bioindustrials, and less so in medical and agricultural opportunities.